Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

tion with InterMune's buyout of future royalties and milestones that would have been due under the previous license agreement with Marnac, Inc. and co-licensor KDL GmbH for the development and commercialization of pirfenidone.

As of December 31, 2007, InterMune had cash, cash equivalents and available-for-sale securities of approximately $235.3 million, compared with $214.5 million at December 31, 2006.

In October 2007, Targanta Therapeutics completed an initial public offering of its common stock, which resulted in the conversion of InterMune's interest in Targanta into approximately 3.0 million shares of Targanta common stock. As of December 31, 2007, InterMune recorded an unrealized gain of $5.7 million on 630,000 of those shares. The 630,000 shares met the criteria to be classified, as available-for-sale, marketable equity securities as they are estimated to qualify for sale within one year.

Dan Welch, President and Chief Executive Officer of InterMune, said, "The fourth quarter was a period of significant progress for InterMune. During the quarter, we significantly improved the potential economics of pirfenidone by eliminating all future royalties and milestones associated with a previous license and we acquired additional pirfenidone intellectual property that we believe will extend the exclusivity period for pirfenidone.

Mr. Welch continued, "We also recently completed the first two dose cohorts in the important Phase 1b study of ITMN-191, our first experience with the compound in patients chronically infected with the hepatitis C virus, and recently announced that we are planning to advance ITMN-191 to a 14-day triple combination study with Pegasus(R) and ribavirin. We look forward to the next 12 months as a pivotal period for InterMune, during which we expect to report the Phase 1b data on ITMN-191, execute a 14-day triple combination study of ITMN-191 and report the results from the Phase 3 CAPACITY program for pirfenidone." '/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Global ... and premium industry insights on the global resorcinol industry. The report highlights the ... of vivid market scenarios and analysis of primary and secondary inputs from the ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace ... for the interpretation and analysis of genomic and ... Fischer has joined the company as Vice ... - http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace ... to integrate, interpret, analyze and explore complex sets ...
(Date:7/30/2015)... July 30, 2015   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... announced that its strategic partner VetStem Biopharma, Inc. ... study of AT-016, an adipose-derived allogeneic stem cell ... of osteoarthritis pain in dogs. The ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, Inc. ... has received the second $1.0M tranche under a ... (SBIR) grant valued at up to $3.0 million ... KL4 surfactant as a potential medical countermeasure to ... Labs was awarded an initial $1.0 million under ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... Calif., March 23 Based on its ... market, Frost & Sullivan presents Nanopoint, Inc. ... Sullivan Award for Product Innovation of the ... represents a highly sophisticated, on-microscope incubator and ...
... 23 PCI Biotech Holding ASA, the Norwegian,drug delivery ... announced that a PCI Biotech-led consortium focused on,effective siRNA ... more than 300,European projects and will receive EUR 1.1 ... The consortium comprises three companies PCI ...
... Fund Will Invest in Biotech Start-up Companies Focused on ... March 23 Merck Serono, a division of Merck ... Serono Ventures, a strategic, corporate venture capital fund to ... biotech start-up companies that have the potential to provide ...
Cached Biology Technology:Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 2Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 3Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 4Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 5PCI Biotech-led Consortium Awarded EUR1.1 m Eurostars Grant for siRNA 2Merck Serono Launches Strategic Venture Capital Fund 2Merck Serono Launches Strategic Venture Capital Fund 3
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... 2009 -- Deteriorating screws in bridges, fish that listen in ... the detected comeback of a long-gone whale, the sound of ... about cowardice. These are just a few of the ... the Acoustical Society of America (ASA), which convenes from May ...
... less-invasive alternative for diabetics who need to take regular ... in check. The common method of drawing blood from ... be painful, inconvenient and time-consuming. Electrical engineers ... of Calgary have patented a device called the Electronic ...
... Sieh, a PhD student at IHBI, is studying the ... bloodstream to form tumour colonies, most often in the ... study which uses a tissue engineering platform technology developed ... investigate the interaction between bones and cancer cells," Ms ...
Cached Biology News:Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 2Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 3Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 4Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 5Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 6Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 7Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 8Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 9Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 10Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 11Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 12Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 13Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 14Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 15Blood testing, mosquito style 23-D research model tackles prostate cancer spread 2
Formulation: Phosphate-buffered saline, pH 7.2, containing 0.09% sodium azide....
... The Luminex 100 Instrument System is ... assays using Upstate's Beadlyte reagents. The ... Dell computer with software version 1.7, ... Delivery System. Upstate offers $2000 in ...
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
Biology Products: